Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 1/20 | 0.43 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | GNG2 | P59768 | 1/20 | 0.38 |
| ▸ | GNB1 | P62873 | 1/20 | 0.38 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.35 |
| ▸ | ATP1A1 | P05023 | 1/20 | 0.34 |
| ▸ | ATP1B1 | P05026 | 1/20 | 0.34 |
| ▸ | ATP1A3 | P13637 | 1/20 | 0.34 |
| ▸ | ATP1B2 | P14415 | 1/20 | 0.34 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.34 |
| ▸ | ATP1A2 | P50993 | 1/20 | 0.34 |
| ▸ | ATP1B3 | P54709 | 1/20 | 0.34 |
| ▸ | FXYD2 | P54710 | 1/20 | 0.34 |
| ▸ | ATP1A4 | Q13733 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28588513 | 0.82 | PSMB5 (0.42) | PSMB5GNG2GNB1 | |
| SCHEMBL1645904 | 0.78 | MAPKAPK2 (0.42) | PSMB5MAPKAPK2GNG2GNB1SMAD3 | |
| SCHEMBL17090849 | 0.77 | CA12 (0.41) | AKR1B1 | |
| SCHEMBL5539483 | 0.76 | MEN1 (0.47) | MAPKAPK2AKR1B1 | |
| SCHEMBL20734708 | 0.74 | AKR1B1 (0.45) | AKR1B1 | |
| SCHEMBL5795754 | 0.68 | MAOA (0.33) | — | |
| SCHEMBL32673162 | 0.68 | AKR1B1 (0.41) | AKR1B1 | |
| SCHEMBL6615687 | 0.67 | MAPKAPK2 (0.39) | MAPKAPK2 | |
| SCHEMBL6616962 | 0.66 | MAPKAPK2 (0.35) | MAPKAPK2 | |
| SCHEMBL11120069 | 0.66 | AKR1B1 (0.40) | AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190169151-A1 | THERAPEUTIC AURONES | Middle Tennessee State University (US) | 2019-06-06 | — | — | US | claimed |
| EP-3442520-A1 | THERAPEUTIC AURONES | Middle Tennessee State University (US) | 2019-02-20 | — | — | EP | claimed |
| WO-2017180644-A1 | THERAPEUTIC AURONES | Middle Tennessee State University (US) | 2017-10-19 | — | — | WO | claimed |
| US-20160287554-A1 | Small Molecule Metal-Activated Protein Inhibition | UNIVERSITY OF SOUTH FLORIDA (US) | 2016-10-06 | — | — | US | claimed |
| US-RE30376-E | 8-Methoxypsoralen | THOMAS C. ELDER, INC. (US) | 1980-08-19 | — | — | US | claimed |
| US-RE30377-E | Process for making ω-chloro-2,3,4-trihydroxyacetophenone | THOMAS C. ELDER, INC. (US) | 1980-08-19 | — | — | US | claimed |
| US-4129575-A | 8-Methoxypsoralen | THOMAS C. ELDER, INC. (US) | 1978-12-12 | — | — | US | claimed |
| US-4129576-A | Process for making ω-chloro-2,3,4-trihydroxyacetophenone | THOMAS C. ELDER, INC. (US) | 1978-12-12 | — | — | US | claimed |
| US-11286245-B2 | Therapeutic aurones | Middle Tennessee State University (US) | 2022-03-29 | — | — | US | disclosed |
| US-20210053933-A1 | THERAPEUTIC AURONES | Middle Tennessee State University (US) | 2021-02-25 | — | — | US | disclosed |
| US-10899727-B2 | Therapeutic aurones | Middle Tennessee State University (US) | 2021-01-26 | — | — | US | disclosed |
| US-20200399238-A1 | THERAPEUTIC AURONES | Middle Tennessee State University (US) | 2020-12-24 | — | — | US | disclosed |
| US-20190169151-A1 | THERAPEUTIC AURONES | Middle Tennessee State University (US) | 2019-06-06 | — | — | US | disclosed |
| EP-3442520-A1 | THERAPEUTIC AURONES | Middle Tennessee State University (US) | 2019-02-20 | — | — | EP | disclosed |
| US-20160287554-A1 | Small Molecule Metal-Activated Protein Inhibition | UNIVERSITY OF SOUTH FLORIDA (US) | 2016-10-06 | — | — | US | disclosed |
| US-20160287554-A1 | Small Molecule Metal-Activated Protein Inhibition | UNIVERSITY OF SOUTH FLORIDA (US) | 2016-10-06 | — | — | US | disclosed |
| US-RE30376-E | 8-Methoxypsoralen | THOMAS C. ELDER, INC. (US) | 1980-08-19 | — | — | US | disclosed |
| US-RE30377-E | Process for making ω-chloro-2,3,4-trihydroxyacetophenone | THOMAS C. ELDER, INC. (US) | 1980-08-19 | — | — | US | disclosed |
| US-4129575-A | 8-Methoxypsoralen | THOMAS C. ELDER, INC. (US) | 1978-12-12 | — | — | US | disclosed |
| US-4129576-A | Process for making ω-chloro-2,3,4-trihydroxyacetophenone | THOMAS C. ELDER, INC. (US) | 1978-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10899727-B2 | Therapeutic aurones | AURKA, PIGS, PRF1 | PSMB5 1433/4885MAPKAPK2 3296/4885AKR1B1 2808/4885 |
| US-20200399238-A1 | THERAPEUTIC AURONES | AURKA, PIGS, PRF1 | PSMB5 1433/4885MAPKAPK2 3296/4885AKR1B1 2808/4885 |
| US-11286245-B2 | Therapeutic aurones | AURKA, PIGS, PRF1 | PSMB5 1433/4885MAPKAPK2 3296/4885AKR1B1 2808/4885 |
| US-20210053933-A1 | THERAPEUTIC AURONES | AURKA, PIGS, PRF1 | PSMB5 1433/4885MAPKAPK2 3296/4885AKR1B1 2808/4885 |
| US-20190169151-A1 | THERAPEUTIC AURONES | AURKA, PIGS, PRF1 | PSMB5 1433/4885MAPKAPK2 3296/4885AKR1B1 2808/4885 |
| US-20160287554-A1 | Small Molecule Metal-Activated Protein Inhibition | PSMB6, PSMD6, PSMA6 | PSMB5 31/4885MAPKAPK2 1333/4885AKR1B1 4088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.